Trial Profile

Phase 1 clinical trial of ART-001

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART-001-AccurEdit-Therapeutics (Primary)
Indications Amyloidosis; Polyneuropathy; Transthyretin-related hereditary amyloidosis
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

06 Jun 2025 Status changed from not stated to planning.
06 Jun 2025 New trial record
29 Aug 2024 According to AccurEdit Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART001, intended for the treatment of transthyretin (ATTR) amyloidosis with polyneuropathy.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com